Updated versions of the leading vaccines for coronavirus have been approved by the US Food and Drug Administration.
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have received approval for their jab, Comirnaty, formulated to target the KP.2 variant of SARS-CoV-2.
The firms said they would begin shipping immediately and that the product would be available in pharmacies, hospitals, and clinics across the USA in the coming days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze